Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04788017
Other study ID # AK0529-3001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 24, 2021
Est. completion date July 22, 2021

Study information

Verified date February 2022
Source Ark Biosciences Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ziresovir following a single ascending oral dose administration in healthy adult subjects under fasted conditions.


Description:

Up to 3 dose cohorts are planned. The ziresovir dose level of each cohort is determined based on the collective clinical and nonclinical data of ziresovir. The proposed dose levels of Cohorts 1, 2 and 3 are 300 mg and up to 600 mg and up to 900 mg, respectively. A total of up to 24 subjects will be randomized with 18 subjects to receive active drug and 6 subjects to receive placebo in a double-blind fashion. Eight subjects will be randomized in each dose cohort, with 6 subjects to receive active drug and 2 subjects o receive placebo.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date July 22, 2021
Est. primary completion date June 14, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Capable of giving written informed consent and complying with study procedures; 2. Between the ages of 18 and 55 years, inclusive; 3. Body mass index (BMI) of 18.0 to 32.0 kg/m2 inclusive and body weight not less than 50 kg; 4. Female subjects must have a negative pregnancy test result at screening; 5. Considered healthy by the Investigator, based on subject's reported medical history, full physical examination, 12-lead ECG, and vital signs; 6. Willing and being able to adhere to study restrictions and to be confined at the Clinical Research Unit. Exclusion Criteria: 1. Clinically significant reported history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug hypersensitivity as determined by the Investigator; 2. Poor venous access; 3. Taken an investigational drug or participated in a clinical trial evaluating an investigational drug or device within 30 days (or 5 half-lives) prior to the study drug dose, whichever is longer; 4. Taken any prescription medications within 14 days or 5 half-lives (whichever is longer) of the study drug dose; 5. Major surgery or hospitalization within 6 months prior to screening that in the Investigator's opinion would put the subject or study conduct at risk, or have any scheduled surgery or hospitalization during the study period; 6. Any condition or finding that in the Investigator's opinion would put the subject or study conduct at risk if the subject were to participate in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ziresovir
Planned treatments are: Cohort 1: 300 mg of ziresovir Cohort 2: up to 600 mg of ziresovir Cohort 3: up to 900 mg of ziresovir
Other:
Placebo
Planned treatments are: Cohort 1: 300 mg of placebo Cohort 2: up to 600 mg of placebo Cohort 3: up to 900 mg of placebo

Locations

Country Name City State
United States Frontage Secaucus New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Ark Biosciences Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary numbers of all AEs The Common Terminology Criteria for Adverse Events (CTCAE) Version 5 will be used to grade AEs through study completion, an average of 22 days
Primary percentages of all AEs The Common Terminology Criteria for Adverse Events (CTCAE) Version 5 will be used to grade AEs through study completion, an average of 22 days
Primary change from baseline in systolic and diastolic blood pressure blood pressure in millimeter of mercury screen/day -1/day 1/day 2/day 3/day4
Primary change from baseline in pulse rate pulse rate in times per minute screen/day -1/day 1/day 2/day 3/day4
Primary change from baseline in respiratory rate respiratory rate in times per minute screen/day -1/day 1/day 2/day 3/day4
Primary change from baseline in oral temperature oral temperature in degree screen/day -1/day 1/day 2/day 3/day4
Primary change from baseline in Prothrombin time/International Normalized Ratio INR is calculated from the PT and allows for worldwide standardization of results. screen/day -1/day 2/day4
Primary change from baseline in Thrombin time Thrombin time in seconds screen/day -1/day 2/day4
Primary change from baseline in activated Partial Thromboplastin time activated Partial Thromboplastin time in seconds screen/day -1/day 2/day4
Primary change from baseline in Hemoglobin (Hgb) count Hemoglobin (Hgb) in gram per liter screen/day -1/day 2/day4
Primary change from baseline in Hematocrit (Hct) screen/day -1/day 2/day4
Primary change from baseline in Platelet count Platelet count per liter screen/day -1/day 2/day4
Primary change from baseline in Red blood cell (RBC) count screen/day -1/day 2/day4
Primary change from baseline in White blood cell (WBC) count with differential screen/day -1/day 2/day4
Primary change from baseline in Specific gravity from urinalysis screen/day -1/day 2/day4
Primary change from baseline in pH from urinalysis screen/day -1/day 2/day4
Primary change from baseline in Protein from urinalysis screen/day -1/day 2/day4
Primary change from baseline in Glucose from urinalysis screen/day -1/day 2/day4
Primary change from baseline in Ketones from urinalysis screen/day -1/day 2/day4
Primary change from baseline in Bilirubin from urinalysis screen/day -1/day 2/day4
Primary change from baseline in Blood from urinalysis screen/day -1/day 2/day4
Primary change from baseline in Nitrites from urinalysis screen/day -1/day 2/day4
Primary change from baseline in Leukocytes from urinalysis screen/day -1/day 2/day4
Primary change from baseline in Urobilinogen from urinalysis screen/day -1/day 2/day4
Primary Incidence of abnormal Microscopic urine analysis screen/day -1/day 2/day4
Primary change from baseline in heart rate-corrected QT interval from resting 12-lead ECGs ECGs will be performed after the subject has been supine for at least 5 minutes screen/day -1/day1/day2/day4
Primary change from baseline in heart rate from resting 12-lead ECGs ECGs will be performed after the subject has been supine for at least 5 minutes screen/day -1/day1/day2/day4
Primary change from baseline in QRS intervals from resting 12-lead ECGs ECGs will be performed after the subject has been supine for at least 5 minutes screen/day -1/day1/day2/day4
Primary change from baseline in treatment-emergent T-wave morphology from resting 12-lead ECGs ECGs will be performed after the subject has been supine for at least 5 minutes screen/day -1/day1/day2/day4
Primary change from baseline in appearance of U-waves from resting 12-lead ECGs ECGs will be performed after the subject has been supine for at least 5 minutes screen/day -1/day1/day2/day4
Primary Incidence of abnormal physical findings full physical examination will be conducted at screening and an abbreviated physical exam will be conducted on Day -1 and Day 2. A symptom-directed physical exam will be conducted on Day 3 and Day 4. screen/day -1/day2/day3/day4
Secondary To characterize the drug concentration of ziresovir following single ascending doses by oral administration in healthy adult male and female subjects 0 (within 90 minutes prior to dosing) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, and 72 hours post-dose
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1